

# Sigachi Laboratories Limited

Unlisted Share Financial Report - ISIN INE368H01018

## Company Overview

Sigachi Laboratories Limited is an Indian pharmaceutical company referenced for manufacturing active ingredients and intermediates, complementing the broader Sigachi group known for excipients. Public materials cite capabilities in compliant production, quality control and customer documentation to support formulations and regulated-market needs. The company supplies domestic and select export customers, focusing on reliability, technical service and adherence to applicable standards.

## Market Snapshot

CURRENT PRICE / SHARE <b>Rs 57.2</b>	MARKET CAP <b>38.63 Cr</b>	P/E RATIO <b>29.55</b>	P/B RATIO <b>0.89</b>
BOOK VALUE / SHARE <b>Rs 58.39</b>	FACE VALUE <b>Rs 10</b>	52 WEEK HIGH <b>Rs 57.2</b>	52 WEEK LOW <b>Rs 57.2</b>
DEBT TO EQUITY <b>0.00</b>	RETURN ON EQUITY <b>3.03%</b>	LOT SIZE <b>1,000 shares</b>	TOTAL SHARES <b>67,53,100</b>

Prices are indicative over-the-counter levels as of 07 July 2026. Actual deal prices may vary.

## Corporate Details

ISIN	<b>INE368H01018</b>
CIN	<b>L24230TG1994PLC018786</b>
PAN	<b>AACCS8220M</b>
Registrar (RTA)	<b>Venture Capital and Corporate Investments</b>
Depository	<b>NSDL &amp; CDSL</b>
Sector	<b>Health Care</b>
Industry	<b>Pharmaceuticals / Lab Services</b>

## Income Statement (Rs Crore)

Particulars	2022	2023	2024	2025
<b>Revenue</b>	<b>260</b>	<b>195</b>	<b>374</b>	<b>312</b>
Cost of Material Consumed	0	0	0	0
Change in Inventory	0	0	0	0
Gross Margins	100%	100%	100%	100%
Employee Benefit Expenses	34	36	39	43
Other Expenses	15	17	93	160
<b>EBITDA</b>	<b>211</b>	<b>142</b>	<b>242</b>	<b>109</b>
OPM	81.15%	72.82%	64.71%	34.94%
Other Income	44	50	62	66
Finance Cost	0	0	0	0
Depreciation & Amortisation	17	19	23	23
<b>EBIT</b>	<b>194</b>	<b>123</b>	<b>219</b>	<b>86</b>
EBIT Margins	74.62%	63.08%	58.56%	27.56%
<b>Profit Before Tax</b>	<b>238</b>	<b>173</b>	<b>281</b>	<b>152</b>
PBT Margins	91.54%	88.72%	75.13%	48.72%
Tax	38	42	84	33
<b>Profit After Tax</b>	<b>200</b>	<b>131</b>	<b>197</b>	<b>119</b>
Net Profit Margin	76.92%	67.18%	52.67%	38.14%
EPS	Rs 2.74	Rs 1.79	Rs 2.69	Rs 1.63

## Balance Sheet - Assets (Rs Crore)

Particulars	2022	2023	2024	2025
Fixed Assets	229	237	321	310
Capital Work in Progress	0	0	0	0
Investments	2,151	1,966	2,663	2,978
Trade Receivables	16	1	20	3
Inventory	0	0	0	0
Other Assets	632	922	730	800
<b>Total Assets</b>	<b>3,028</b>	<b>3,126</b>	<b>3,734</b>	<b>4,091</b>

## Balance Sheet - Liabilities (Rs Crore)

Particulars	2022	2023	2024	2025
Share Capital	731	731	731	731
Face Value	Rs 10	Rs 10	Rs 10	Rs 10
Reserves	2,244	2,343	2,870	3,202
Borrowings	0	0	0	0
Trade Payables	0	0	0	0
Other Liabilities	53	52	133	158
<b>Total Liabilities</b>	<b>3,028</b>	<b>3,126</b>	<b>3,734</b>	<b>4,091</b>

## Cash Flow Statement (Rs Crore)

Particulars	2022	2023	2024	2025
<b>Profit Before Tax</b>	<b>237</b>	<b>173</b>	<b>281</b>	<b>152</b>
Operating Profit Before Working Capital	74	77	80	82
Change in Receivables	-16	15	-19	17
Change in Inventories	0	0	0	0
Change in Payables	0	0	0	0
Other Changes	-236	0	-210	-1
Working Capital Change	-252	15	-229	16
Cash Generated From Operations	-178	92	-149	98
Tax	-38	-44	-41	-46
<b>Cash Flow From Operations</b>	<b>-216</b>	<b>48</b>	<b>-190</b>	<b>52</b>
Purchase of PPE	-1.6	-27	-108	-12
Sale of PPE	0.5	0	2	0
<b>Cash Flow From Investment</b>	<b>54</b>	<b>243</b>	<b>-136</b>	<b>90</b>
Borrowing	0	0	0	0
Dividend	0	0	0	0
Equity	0	0	0	0
Others From Financing	0	0	0	0
<b>Cash Flow from Financing</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Net Cash Generated</b>	<b>-162</b>	<b>291</b>	<b>-326</b>	<b>142</b>
Cash at the Start	243	80	371	45
Cash at the End	81	371	45	187

## Key Ratios

Particulars	2022	2023	2024	2025
Operating Profit Margin	81.15%	72.82%	64.71%	34.94%
Net Profit Margin	76.92%	67.18%	52.67%	38.14%
Earning Per Share (Diluted)	Rs 2.74	Rs 1.79	Rs 2.69	Rs 1.63

Source: Compiled by Neoma Capital research. Data as of FY2025. Figures may be restated in subsequent filings.